Aldexa Therapeutics

Aldexa Therapeutics develops treatments for the dry form of age-related macular degeneration eye disease.

Aldexa Therapeutics, Inc. develops treatments for the dry form of age-related macular degeneration eye disease that may lead to blindness. It activities include the development of drugs to inhibit the formation of toxic metabolites that accumulate in the back of the eye. Aldexa Therapeutics, Inc. was formerly known as Neuron Systems, Inc. The company was incorporated in 2004 and is based in Burlington, Massachusetts. The company changed its name to Aldeyra Therapeutics, Inc. on March 17, 2014. Aldeyra held an initial public offering on May 7, 2014.